Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
GOSS Catalyst Timeline
Dated clinical, regulatory and corporate events for Gossamer Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Gossamer Bio, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How GOSS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | seralutinib (GB002) | NDA Submission | NDA |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Seralutinib Small MoleculesNCT03926793 | Pulmonary Arterial Hypertension | Phase 3 | COMPLETED | 728 | May 5, 2021 | ||||||
| Seralutinib Small MoleculesCompletedNCT04456998 | Pulmonary Artery Hypertension | Phase 2 | COMPLETED | 86 | Nov 1, 2022 | ||||||
| Seralutinib Small MoleculesCompletedNCT03473236 | Safety Issues | Phase 1 | COMPLETED | 66 | Dec 3, 2018 | ||||||
| GB004 Small MoleculesCompletedNCT03860896 | Ulcerative Colitis | Phase 1 | COMPLETED | 34 | Dec 17, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every GOSS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Gossamer Bio | Phase 3 | 2026-05-07 | failed to meet the primary endpointRead More | GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallStRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Aranda RichardOfficer (Chief Medical Officer) | Disposition | -562,500 | $0.00 | 03/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GOSS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 0.6 % (-45.5 %) | 5.06 M | 426.99 K | -84.3% ( -2.29 M) |
Ownership Trends
GOSS Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How GOSS ranks across every disease it competes in
GOSS News
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio reported its third quarter 2026 financial results, highlighting the submission of its first New Drug Application (NDA) for seralutinib to the FDA for pulmonary arterial hypertension. The company secured $25 million upfront from a structured private placement, with potential for an additional $125 million upon FDA acceptance. Gossamer also completed a reverse stock split to comply with Nasdaq requirements.
Read more →Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Gossamer Bio has submitted a New Drug Application to the U.S. FDA for seralutinib, aimed at treating pulmonary arterial hypertension (PAH). This marks a significant step in the drug's development and potential commercialization. The application reflects the company's commitment to addressing serious health conditions associated with pulmonary hypertension.
Read more →Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Gossamer Bio has appointed Greg Ciongoli to its Board of Directors, effective September 16, 2026. Ciongoli will also be a member of the Audit Committee. This appointment is expected to enhance the company's leadership and governance as it focuses on developing treatments for pulmonary arterial hypertension and related conditions.
Read more →Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Gossamer Bio, Inc. has announced a 1-for-80 reverse stock split to enhance its stock structure. The company has filed a Certificate of Amendment with the Delaware Secretary of State. This move is aimed at improving market perception and potentially attracting more institutional investors.
Read more →Gossamer Bio Announces 1-for-80 Reverse Stock Split
Gossamer Bio, Inc. has announced a 1-for-80 reverse stock split of its common stock, which is intended to reduce the number of outstanding shares. This decision comes amid the company's focus on developing seralutinib for pulmonary arterial hypertension. The board aims to enhance the stock's marketability and align it with compliance requirements.
Read more →Gossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer Bio, Inc. will present at the Cantor Global Healthcare Conference from September 9-11, 2026. The presentation will focus on their clinical-stage product, seralutinib, aimed at treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This event is expected to boost the company's visibility in the healthcare sector.
Read more →Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Gossamer Bio has announced a significant private placement financing of up to $250 million, which includes $150 million in committed capital. This funding is intended to support the development of seralutinib, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, as it progresses towards potential FDA approval.
Read more →Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio, a clinical-stage biopharmaceutical firm, announced its financial results for the second quarter of 2026. The company is focused on developing seralutinib for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The update reflects Gossamer's ongoing efforts to strengthen its business.
Read more →Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
Gossamer Bio has announced significant regulatory and corporate updates, including positive feedback from the FDA following a Pre-NDA Type B meeting. The company has also reacquired worldwide rights to seralutinib, which is intended for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. These developments signal a promising direction for Gossamer's future in the biopharmaceutical market.
Read more →Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Gossamer Bio, Inc. has announced the conversion rate for its 7.50% convertible senior secured first lien notes due in 2030, along with the exercise price for purchase warrants. This announcement is part of the company's ongoing financial strategy. Further details regarding the implications of these changes were not provided in the article.
Read more →Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. has announced the final tender results for its exchange offer and consent solicitation concerning existing convertible notes. The announcement provides details about the completion of the exchange offer, but lacks specific financial figures or implications for stakeholders. The company aims to streamline its capital structure through this initiative.
Read more →Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. has announced the early tender results and early settlement for its exchange offer and consent solicitation related to existing convertible notes. The announcement indicates a strategic move by the company but lacks detailed information on the implications or outcomes of the offer.
Read more →Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. has announced an extension of the early tender date for its exchange offer and consent solicitation related to existing convertible notes. This decision is part of the company's ongoing financial strategies. Further details regarding the implications of this extension were not provided in the announcement.
Read more →Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio has released its financial results for the first quarter of 2026 along with a business update. The details of the financial performance and any strategic plans or developments were not disclosed in the article. Further insights into the company's direction or upcoming initiatives were also not provided.
Read more →Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
Gossamer Bio, Inc. has announced an exchange offer and consent solicitation aimed at eliminating over $120 million of debt. This initiative has received support from existing noteholders, indicating confidence in the company's financial strategy. The move is part of Gossamer's efforts to strengthen its balance sheet and improve financial stability.
Read more →Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
Gossamer Bio has scheduled the announcement of its first quarter 2026 financial results. The company will host a conference call and webcast on May 18, 2026, to discuss the results. Further details regarding the financial performance and future outlook may be shared during this event.
Read more →Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Gossamer Bio reported its financial results for Q4 and full-year 2025, highlighting the performance of seralutinib in treating pulmonary arterial hypertension (PAH). Despite missing the primary endpoint in the PROSERA study, the company noted significant improvements in certain patient subgroups. Gossamer plans to engage with the FDA regarding future regulatory strategies while managing operational costs.
Read more →Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Gossamer Bio announced topline results from the Phase 3 PROSERA Study of seralutinib for pulmonary arterial hypertension (PAH). Although the primary endpoint did not meet the stringent statistical threshold, seralutinib demonstrated significant improvements in six-minute walk distance (6MWD) and showed efficacy in high-risk patient subgroups. The company plans to discuss these results with the FDA for potential next steps.
Read more →Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 8, 2026
Gossamer Bio has announced the approval of stock option grants to three non-executive employees as part of its 2023 Employment Inducement Incentive Award Plan. The grants, effective January 5, 2026, allow for the purchase of up to 212,500 shares at an exercise price of $2.74 each. This initiative aims to attract and retain talent while supporting the company's focus on developing treatments for pulmonary hypertension.
Read more →Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
Gossamer Bio reported its financial results for Q3 2025, highlighting a cash position of $180 million and the activation of the first site for its Phase 3 SERANATA study in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company anticipates topline results from the ongoing PROSERA Phase 3 study by February 2026. Despite the positive developments, Gossamer recorded a net loss of $48.2 million for the quarter, raising concerns over rising research and development expenses. The firm emphasizes its commitment to addressing unmet medical needs in pulmonary hypertension, supported by ongoing collaborations and community engagement.
Read more →